How John McCain died
John McCain died from glioblastoma, an aggressive primary brain cancer, on August 25, 2018. He was 81. After a glioblastoma diagnosis in July 2017, he underwent surgery, chemotherapy, and immunotherapy while managing symptoms and complications. In the final year, care focused on comfort and quality of life. His family paused aggressive treatment to prioritize palliative care. McCain’s passing followed a period of neurological decline associated with cancer progression. This verified explainer outlines the medical timeline, treatment choices, and context around his death.
Medical background and diagnosis
McCain’s glioblastoma was first identified in July 2017, about one year before his death. The tumor was located in the left temporal lobe and was classified as a grade 4 astrocytoma, the most common and aggressive form of primary brain cancer. The initial symptoms included neurological deficits prompting imaging and biopsy confirmation. At diagnosis, the tumor was partially resected via surgery to relieve pressure and reduce mass effect. Subsequent treatment combined radiation and chemotherapy, including temozolomide, followed by maintenance immunotherapy with checkpoint inhibitors. These interventions aimed to control tumor growth and prolong stability rather than cure, given the inherently poor prognosis of glioblastoma.
Timeline of care and progression
McCain’s glioblastoma treatment followed a standard aggressive multimodal approach. Surgery was performed soon after diagnosis to remove as much visible tumor as safely possible. Radiation was administered shortly thereafter, typically over several weeks, accompanied by concurrent temozolomide chemotherapy. After completing radiation, he continued temozolomide cycles and later added immunotherapy, a strategy intended to leverage immune checkpoint inhibition against tumor antigens. Despite these measures, glioblastoma often recurs due to infiltrative growth patterns. By early 2018, scans showed evidence of progression, leading to a shift toward palliative symptom management. Ultimately, comfort-focused care replaced active tumor-directed therapy in his final months.
End-of-life care and cause of death
McCain’s death was caused by complications related to glioblastoma, including metastatic spread within the central nervous system and subsequent neurological impairment. During his final year, he experienced declining neurological function, likely due to tumor progression and associated edema. At the request of his family and medical team, interventions shifted away from curative intent to comfort care, emphasizing pain control, symptom relief, and dignity. He died at home with hospice support surrounded by family. While the immediate physiological cause was multi-factorial, including infection risk and cancer-related decline, the underlying driver remained glioblastoma progression. This reflects the typical trajectory for patients with recurrent, refractory high-grade glioma.
Glioblastoma overview and prognosis
- Glioblastoma is a grade 4 astrocytoma and the most common primary malignant brain tumor in adults.
- Median overall survival is approximately 12 to 18 months with standard combined modality treatment (surgery, radiation, and temozolomide chemotherapy).
- Few patients achieve long-term remission; five-year survival remains below 7% in population-based series.
- Immunotherapy and emerging targeted regimens may extend survival for select patients but do not typically cure the disease.
- Recurrent glioblastoma often requires palliative management when further aggressive therapy is not pursued.
Care choices and family statements
McCain’s family publicly stated that he elected to forgo aggressive therapies in his last months, focusing instead on quality of life and comfort. This decision aligned with prior conversations about goals of care in advanced illness. His care team supported this transition by coordinating hospice services, managing symptoms such as pain and agitation, and providing psychological and spiritual support. Public statements emphasized respect for his wishes and gratitude for his legacy. The shift from active cancer treatment to palliative care is common for patients with progressive glioblastoma when potential benefits of further therapy are limited by toxicity and modest gains in survival.
Public reaction and legacy context
McCain’s death prompted widespread remembrance of his military service, political career, and advocacy for civility and bipartisanship. Tributes highlighted his resilience during treatment and willingness to speak openly about prognosis and care preferences. His experience influenced public discourse around advanced cancer care, clinical trial participation, and end-of-life planning. While opinions about his policies varied, many noted the dignity with which he and his family navigated a difficult illness. His case remains a reference point in discussions about patient autonomy, goals of care, and the realities of glioblastoma.
Key facts at a glance
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Date of death | August 25, 2018 | Official announcements and obituaries |
| Age at death | 81 years | Biographical records |
| Primary cause | Complications of glioblastoma | Family statements and medical reporting |
| Initial diagnosis | July 2017 | Public medical disclosures |
| Treatment approach | Surgery, radiation, temozolomide, immunotherapy | Treatment summaries and oncology reports |
| Care choice near death | Palliative/hospice care, no aggressive cancer-directed therapy | Family statements |
Summary
John McCain died from glioblastoma, a highly aggressive brain cancer, on August 25, 2018. His care journey spanned surgery, radiation, chemotherapy, and immunotherapy, followed by a voluntary transition to comfort-focused care in his final months. Glioblastoma’s poor prognosis and limited treatment options explain the shift to palliative management. His death underscores the challenges of high-grade glioma and highlights patient and family decisions in advanced illness. Verified details remain consistent across medical reporting, obituaries, and statements from McCain’s care team.